Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;6(4):19.
doi: 10.7603/s40681-016-0019-z. Epub 2016 Nov 16.

Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review

Affiliations

Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review

Te-Chun Hsieh et al. Biomedicine (Taipei). 2016 Nov.

Abstract

Hepatocellular carcinoma (HCC) is a disease usually diagnosed in its advanced-stage, and is frequently not amenable to curative surgical treatment. Also, HCC is resistant to chemotherapy and less vulnerable to radiation therapy compared to normal hepatic parenchyma. Both of these facts render the efficacy of adjuvant and palliative treatments problematic. Selective internal radiation therapy (SIRT) with 90Y-bearing microspheres is characterized by preferentially delivering substantially high doses of radiation to a liver tumor dose simultaneously limiting the damage to its non-tumorous cells, providing an opportunity for effective local tumor control and even tumor regression therapy. The current article reviews the specific characters, dosimetry, possible applications, and special considerations toward the pre-existing radiation therapy of 90Y microsphere SIRT in treating HCC.

Keywords: 90Y microspheres; 99mTc macroaggregated albumin; External beam radiation therapy; Hepatocellular carcinoma; Radiation lobectomy; Selective internal radiation therapy; Transarterial chemoembolization.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141:861–76. doi: 10.1007/s00432-014-1806-0. - DOI - PMC - PubMed
    1. Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. Radiographics. 2008;28:101–17. doi: 10.1148/rg.281075115. - DOI - PubMed
    1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73 e1. - PMC - PubMed
    1. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology. 2001;33:62–5. doi: 10.1053/jhep.2001.21041. - DOI - PubMed
    1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–28. doi: 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E. - DOI - PubMed